Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialDaniel D. Mikol, Bernard M.J. Uitdehaag, Douglas Jeffery et al.|The Lancet Neurology|2008Cited by 484
Scoring treatment response in patients with relapsing multiple sclerosisMaria Pia Sormani, Nicola De Stefano, ML Stromillo et al.|Multiple Sclerosis Journal|2012Cited by 258
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trialGıancarlo Comı, Ludwig Kappos, Bryan T. Hennessy et al.|The Lancet Neurology|2011Cited by 214